BioCatalystWatch
EIKNWorkspace / EIKN / OverviewCompany library
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. (EIKN)

Website

Price
Market cap
Next catalystExpected 2H 2026EIK1004 — EIK1004-001 monotherapy · Dosing completionCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

EIK1001

TLR7 × TLR8

PreINDP1P2P3FilingApproved
EIK1003

PARP1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1006

AR × AR LBD

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1005

WRN

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1004

PARP1

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

EIK1005

WRN

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1006

AR × AR LBD

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1004

PARP1

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1003

PARP1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

EIK1001

TLR7 × TLR8

PreINDP1P2P3FilingApproved

Other pipelines

EIK1001

TLR7 × TLR8

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

EIKN SEC archive